Therapeutics (HOTH) announced it has expanded its artificial intelligence initiative through a new Nvidia (NVDA) AI Enterprise subscription license to accelerate data-driven drug development, preclinical modeling, and predictive analytics. Under the new entitlement and renewal agreement, Hoth Therapeutics has secured annual Nvidia AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics expands intellectual property portfolio for HT-001
- Hoth Therapeutics Faces Digital Asset Industry Challenges
- Hoth Therapeutics submits CTA to EMA to expand Phase II trial of HT-001
- Hoth Therapeutics’ cancer therapeutic HT-KIT shows efficacy, safety
- Hoth Therapeutics Renews CEO Contract Amidst Patent Filing